The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Pre-treatment biomarkers to predict response to T-cell engagers in multiple myeloma
Paola Neri, MD, PhD, University of Calgary, Calgary, Canada, discusses the development of pre-treatment biomarkers to predict response to T-cell engager therapy in multiple myeloma. She highlights soluble BCMA as a potential clinically useful biomarker, while ongoing work to characterize BCMA mutations could enable personalized treatment selection and identify patients who may benefit from another BCMA-directed therapy or a switch to GPRC5D targeting. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
